期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤靶向治疗及其相应分子靶点检测

原文传递
导出
摘要 20世纪70年代后期，肿瘤生物学研究深入到分子水平，并发现肿瘤中癌基因突变和扩增；抑癌基因失活和丢失；基因转录和蛋白产物异常；信号转导通路异常活化；细胞周期调节失控，导致肿瘤细胞不受控制地增殖；细胞凋亡抑制肿瘤新生血管形成。肿瘤分子生物学研究阐明了肿瘤发生发展中的许多以前不为人知的分子机制，为肿瘤的药物治疗提供了一种新的模式。即依据已知肿瘤发生中涉及的异常分子和基因。设计和研制针对这些已知的特定分子和基因的靶点药物，选择性杀伤肿瘤细胞，这种治疗方法称为肿瘤的靶向治疗。靶向药物只作用于有特定靶点的肿瘤。特异性强，能选择性杀伤肿瘤细胞，治疗效果明显。对正常细胞损害较小，不良反应通常少而轻微，不同于传统的化学治疗。
作者 朱雄增 史恩溢
机构地区 复旦大学附属肿瘤医院病理科复旦大学上海医学院肿瘤学系
出处 《中华内科杂志》 CAS CSCD 北大核心 2008年第9期779-781,共3页 Chinese Journal of Internal Medicine
关键词 肿瘤靶向治疗 分子靶点 杀伤肿瘤细胞 肿瘤新生血管形成 细胞周期调节 癌基因突变 肿瘤分子生物学 检测
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献18

  • 1Ross JS, Schenkein DP, Pietrusko R, et al. Targeted therapies for cancer 2004. Am J Clin Pathol,2004 ,122 :598-609.
  • 2Dowsett M, Bartlett J, Ellis IO, et al. Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 37 centres. J Pathol,2003 ,199 :418-423.
  • 3曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量：65
  • 4Isola J, Tanner M, Forsyth A, et al. Intedaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res, 2004, 10: 4793-4798.
  • 5Blanke CD, yon Mehren M, Joensuu H, et al. Long-term follow-up of a phase Ⅱ randomized trial in advanced gastrointestinal stromal tumors (GIST) patients(pts) treated with imatinib mesylate. American Society of Clinical Oncology, Gebrgia, 2006. http ://www. asco. org.
  • 6Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science ,2004,304 : 1497-1500.
  • 7Trail PA, Bianchi AB. Monoclonal antibody drug conjugates in the treatment of cancer. Curt Opin Immunol,1999,11:584-588.
  • 8Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol,2005,23 : 1147-1157.
  • 9Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin 0nco1,1999,26(4 Suppl 12) :71-77.
  • 10Saltz LB, Meropol N J, Loehrer PJ Sr, et al. Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol,2004, 22 : 1201-1208.

二级参考文献17

  • 1Van de Vijver MJ. Assessment of the need and appropriate method for testing for the human epidermal growth factor receptor-2 (HER2).Eur J Cancer, 2001, 37Suppl 1: 11-17.
  • 2Ross JS, Gray GS. Targeted therapy for cancer: the HER-2/neu and Herceptin story. Clin Leadersh Manag Rev, 2003, 17:333-340.
  • 3Vogel-C, Cobieigh MA, Tripathy D? et al. First-line, single-agent Herceptin ( R ) ( trastuzumab ) in metastatic breast cancer: a preliminary report. Eur J Cancer, 2001, 37 Suppl 1:25-29.
  • 4Hammock L, Lewis M, Phillips C, et al. Strong Her-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol, 2005,36 : 1043-1047.
  • 5Ross JS, Fletcher JA, Linette GP, et al. The HER-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.Oncologist, 2003, 8:307-325.
  • 6Hicks DG, Tubbs RR. Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum Pathol, 2005, 36:250-261.
  • 7Yarden Y. Biology of HER2 and its importance in breast cancer.Oncology, 2001, 61 Suppl 2:1-13.
  • 8Reed W, Hannisdal E, Boehler PJ, et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years.Cancer, 2000,88:804-813.
  • 9Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive,node-positive breast cancer. J Clin Oncol, 2000, 18:3471-3479.
  • 10Schmidt M, Lewark B, Kohlschmidt N, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res,2005,7 :R256-R266.

共引文献64

中华内科杂志
2008年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部